References

GLP-1 Medication use for type 2 diabetes has soared

10.1001/jama.2024.18219 · 2024 · External reference

Clinical consequences of delayed gastric emptying with GLP-1 receptor agonists and tirzepatide

10.1210/clinem/dgae719 · 2024 · External reference

Effects of GLP-1 and its analogs on gastric physiology in diabetes mellitus and obesity

10.1007/5584_2020_496 · 2021 · External reference

Association of glucagon-like peptide-1 receptor agonist treatment with gastric residue in an esophagogastroduodenoscopy

10.1111/jdi.14005 · 2023 · External reference

Relationship between perioperative semaglutide use and residual gastric content: a retrospective analysis of patients undergoing elective upper endoscopy

10.1016/j.jclinane.2023.111091 · 2023 · External reference

Impact of glucagon-like peptide-1 receptor agonists (GLP-1RA) on food content during esophagogastroduodenoscopy (EGD)

10.1177/10600280211055804 · 2022 · External reference

Multisociety clinical practice guidance for the safe use of glucagon-like peptide-1 receptor agonists in the perioperative period

10.1016/j.cgh.2024.10.003 · 2024 · External reference

The role of delayed gastric emptying and impaired oesophageal body motility

10.1016/j.bpg.2010.09.003 · 2010 · External reference

Influence of gastric emptying on gastro-esophageal reflux: a combined pH-impedance study

10.1111/nmo.12181 · 2013 · External reference

Predictor of slower gastric emptying in gastroesophageal reflux disease: survey of an Asian-Pacific cohort

10.1111/jgh.14572 · 2019 · External reference

Patients with symptoms of delayed gastric emptying have a high prevalence of oesophageal dysmotility, irrespective of scintigraphic evidence of gastroparesis

10.1136/bmjgast-2017-000169 · 2017 · External reference

Preoperative fasting and the risk of pulmonary aspiration: a narrative review of historical concepts, physiological effects, and new perspectives

10.1016/j.bjao.2024.100282 · 2024 · External reference

Increased risk of aspiration pneumonia associated with endoscopic procedures among patients with glucagon-like peptide 1 receptor agonist use

10.1053/j.gastro.2024.03.015 · 2024 · External reference

Effects of glucagon-like peptide-1 receptor agonists on endoscopy outcomes: systematic review and meta-analysis

10.1016/j.gie.2024.10.011 · 2025 · External reference

Clinical outcomes and safety of upper endoscopy while on glucagon-like peptide-1 receptor agonists

10.1016/j.cgh.2024.03.013 · 2025 · External reference

Effects of glucagon-like peptide-1 receptor agonists on upper gastrointestinal endoscopy: a meta-analysis

10.1016/j.cgh.2024.07.021 · 2025 · External reference

Glucagon-like peptide-1 receptor agonists do not increase aspiration during upper endoscopy in patients with diabetes

10.1016/j.cgh.2024.04.038 · 2025 · External reference

Glucagon-like peptide-1 receptor agonist use and the risk of residual gastric contents and aspiration in patients undergoing GI endoscopy: a systematic review and a meta-analysis

10.1016/j.gie.2024.12.019 · 2025 · External reference

Gastrointestinal adverse events associated with semaglutide: a pharmacovigilance study based on FDA adverse event reporting system

10.3389/fpubh.2022.996179 · 2022 · External reference

Association between different GLP-1 receptor agonists and gastrointestinal adverse reactions: a real-world disproportionality study based on FDA adverse event reporting system database

10.3389/fendo.2022.1043789 · 2022 · External reference

Signals of gastroesophageal reflux disease caused by incretin-based drugs: a disproportionality analysis using the Japanese adverse drug event report database

10.1186/s40780-018-0109-z · 2018 · External reference

Shorter-acting glucagon-like peptide-1 receptor agonists are associated with increased development of gastro-oesophageal reflux disease and its complications in patients with type 2 diabetes mellitus: a population-level retrospective matched cohort study

10.1136/gutjnl-2023-329651 · 2024 · External reference

Effects of lixisenatide versus liraglutide (short- and long-acting glp-1 receptor agonists) on esophageal and gastric function in patients with type 2 diabetes

10.2337/dc20-0720 · 2020 · External reference

Liraglutide effects on upper gastrointestinal investigations: implications prior to bariatric surgery

10.1007/s11695-018-3249-1 · 2018 · External reference

Distribution of esophageal motor disorders in diabetic patients with dysphagia

10.1097/mcg.0000000000000894 · 2017 · External reference

Trends in glucagon-like peptide 1 receptor agonist use, 2014 to 2022

10.1016/j.japh.2023.10.002 · 2024 · External reference

Increased prevalence of eosinophilic esophagitis in patients with chronic rhinosinusitis

10.1177/19458924221116162 · 2022 · External reference

Esophageal function tests are not associated with barium swallow findings in advanced lung disease

10.1007/s00455-020-10113-2 · 2020 · External reference

Beyond the Eckardt score: patient-reported outcomes measures in esophageal disorders

10.1007/s11894-021-00831-4 · 2021 · External reference

Development and validation of the brief esophageal dysphagia questionnaire

10.1111/nmo.12889 · 2016 · External reference

The reflux disease questionnaire: a measure for assessment of treatment response in clinical trials

10.1186/1477-7525-6-31 · 2008 · External reference

Validity and reliability of the reflux symptom index (RSI)

10.1016/s0892-1997(02)00097-8 · 2002 · External reference

Improved assessment of bolus clearance in patients with achalasia using high-resolution impedance manometry

10.1016/j.cgh.2017.11.019 · 2018 · External reference

Reflux disease questionnaire scoring and utilization: a scoping review

10.1177/26345161231198622 · 2023 · External reference

Is the reflux disease questionnaire useful for identifying GERD according to the Montreal definition?

10.1186/1471-230x-14-17 · 2014 · External reference

Revisiting the complexity of GLP-1 action from sites of synthesis to receptor activation

10.1210/endrev/bnaa032 · 2021 · External reference

Identification of expression and function of the glucagon-like peptide-1 receptor in colonic smooth muscle

10.1016/j.peptides.2018.11.007 · 2019 · External reference

Glucagon-like peptide-1 inhibits prandial gastrointestinal motility through myenteric neuronal mechanisms in humans

10.1210/jc.2017-02006 · 2018 · External reference

Exogenous glucagon-like peptide 1 reduces contractions in human colon circular muscle

10.1530/joe-13-0525 · 2014 · External reference

Distinct identity of GLP-1R, GLP-2R, and GIPR expressing cells and signaling circuits within the gastrointestinal tract

10.3389/fcell.2021.703966 · 2021 · External reference

Gastrointestinal effects of GLP-1 receptor agonists: mechanisms, management, and future directions

10.1016/s2468-1253(24)00188-2 · 2024 · External reference

Regurgitation, eructation, and supragastric belch: retrograde esophageal motility, disorders, and treatment

10.1097/mog.0000000000001059 · 2024 · External reference

Colonic fermentation influences lower esophageal sphincter function in gastroesophageal reflux disease

10.1053/gast.2003.50159 · 2003 · External reference

Predictors of abnormal functional luminal impedance planimetry findings in non-mechanical esophagogastric junction outflow obstruction

10.1007/s10620-020-06726-0 · 2021 · External reference

Opioids in gastroenterology: treating adverse effects and creating therapeutic benefits

10.1016/j.cgh.2017.05.014 · 2017 · External reference

GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus

10.1038/nrendo.2012.140 · 2012 · External reference

Accuracy of administrative health data for the diagnosis of upper gastrointestinal diseases

10.1007/s00464-006-9136-1 · 2007 · External reference